Piramal Pharma Limited Sustainability Profile
Piramal Pharma Limited, a prominent player in the global pharmaceutical industry, is headquartered in India and operates extensively across key regions, including North America, Europe, and Asia. Founded in 1988, the company has achieved significant milestones, establishing itself as a leader in both contract development and manufacturing, as well as in the formulation of complex generics. Piramal Pharma's core offerings include a diverse range of pharmaceutical products and services, with a strong emphasis on innovative drug delivery systems and advanced therapies. Their commitment to quality and sustainability sets them apart in a competitive market. With a robust portfolio and a focus on research and development, Piramal Pharma Limited continues to enhance its market position, contributing to healthcare solutions worldwide.
DitchCarbon Score
How does Piramal Pharma Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Piramal Pharma Limited's score of 45 is higher than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Piramal Pharma Limited's reported carbon emissions
In 2025, Piramal Pharma Limited reported total carbon emissions of approximately 32,279,000 kg CO2e for Scope 1 and about 51,363,000 kg CO2e for Scope 2 (market-based). The combined total for Scope 1 and Scope 2 emissions reached about 83,642,000 kg CO2e. In 2024, the company recorded approximately 43,383,000 kg CO2e for Scope 1 and about 62,210,000 kg CO2e for Scope 2, resulting in a total of around 105,593,000 kg CO2e. The 2023 figures showed a total of about 98,073,000 kg CO2e for Scope 1 and Scope 2 emissions, alongside significant Scope 3 emissions of approximately 450,639,000 kg CO2e. Piramal Pharma has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 greenhouse gas emissions by 42% by FY2030, using FY2022 as the baseline. This target aligns with the 1.5°C decarbonisation pathway recommended by the Science-Based Targets initiative (SBTi). Additionally, the company aims to cut Scope 3 emissions by 25% within the same timeframe, focusing on emissions from purchased goods and services, fuel and energy-related activities, and the use of sold products. The company has applied for SBTi approval for these targets, demonstrating its commitment to addressing climate change and reducing its carbon footprint.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Scope 1 | 41,396,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 74,243,220 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 477,407,000 | - | 000,000,000 | - | - |
How Carbon Intensive is Piramal Pharma Limited's Industry?
How Carbon Intensive is Piramal Pharma Limited's Location?
Piramal Pharma Limited's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Piramal Pharma Limited has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Frequently Asked Questions
Common questions about Piramal Pharma Limited's sustainability data and climate commitments